Emerging Trends in Vaccine Development Integrating Pharmaceutical Science with Public Health

Article Sidebar

PDF
Published: Apr 25, 2025
DOI: https://doi.org/10.55885/jchp.v5i1.573
Keywords:
Vaccine Development, Mrna Technology, Public Health, Policy Frameworks

Main Article Content

Vausan Mafuts
Faculty of Medicine, Muslim University of Indonesia, Indonesia

Abstract

The rapid evolution of vaccine science accelerated by the COVID-19 pandemic has generated profound shifts in the landscape of global health, biotechnology, and public policy. This study conducts a thematic scoping review to critically examine emerging paradigms in vaccine development, focusing on their scientific innovation, translational pathways, regulatory integration, and public health implementation. Drawing on peer-reviewed literature and strategic policy documents from 2018 to 2025, the analysis identifies four interrelated domains: (1) technological innovation in platforms such as mRNA, saRNA, AI-guided antigen design, and nanocarrier systems; (2) translational pharmacology, including the challenges of real-world implementation, personalized immunization, and genomically-informed vaccinology; (3) policy integration and the tensions between global regulatory architectures, intellectual property regimes, and regional manufacturing autonomy; and (4) public health implementation, where infrastructure, sociopolitical trust, and health equity shape uptake and access. Across all domains, the study finds that scientific progress alone is insufficient to ensure global immunization justice. Instead, the translation of vaccine innovation into equitable impact is mediated by structural inequalities, geopolitical asymmetries, and the uneven capacities of health systems. The findings underscore the urgent need for ethically grounded, interdisciplinary strategies that align biotechnological advancement with equitable public health outcomes, particularly in low- and middle-income contexts.

Article Details

How to Cite
Mafuts, V. (2025). Emerging Trends in Vaccine Development Integrating Pharmaceutical Science with Public Health . Journal of Community Health Provision, 5(1), 38-49. https://doi.org/10.55885/jchp.v5i1.573
Issue
Vol. 5 No. 1 (2025): Journal of Community Health Provision
Section
Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

References

Aswathy, R., & Sumathi, S. (2024). The evolving landscape of cervical cancer: breakthroughs in screening and therapy through integrating biotechnology and artificial intelligence. Molecular Biotechnology, 1-17. https://doi.org/10.1007/s12033-024-01124-7

Blass, E., & Ott, P. A. (2021). Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nature reviews Clinical oncology, 18(4), 215-229. https://doi.org/10.1038/s41571-020-00460-2

Bok, K., Sitar, S., Graham, B. S., & Mascola, J. R. (2021). Accelerated COVID-19 vaccine development: milestones, lessons, and prospects. Immunity, 54(8), 1636-1651. https://doi.org/10.1016/j.immuni.2021.07.017

Bourgois, P., Holmes, S. M., Sue, K., & Quesada, J. (2017). Structural vulnerability: operationalizing the concept to address health disparities in clinical care. Academic Medicine, 92(3), 299-307. https://doi.org/10.1097/ACM.0000000000001294

Bukhari, M. H., Syed, M., & Zain, S. (2021). The differences between traditional vaccines and RNA vaccines: safety, efficacy, reliability and future of COVID-19 vaccines. Annals of King Edward Medical University, 27(2).

Cao, P., Xu, Z. P., & Li, L. (2022). Tailoring functional nanoparticles for oral vaccine delivery: Recent advances and future perspectives. Composites Part B: Engineering, 236, 109826. https://doi.org/10.1016/j.compositesb.2022.109826

Cheng, J., Liang, T., Xie, X. Q., Feng, Z., & Meng, L. (2024). A new era of antibody discovery: an in-depth review of AI-driven approaches. Drug Discovery Today, 103984. https://doi.org/10.1016/j.drudis.2024.103984

Dawadi, S. (2020). Thematic analysis approach: A step by step guide for ELT research practitioners. Journal of NELTA, 25(1-2), 62-71. https://doi.org/10.3126/nelta.v25i1-2.49731

Defendi, H. G. T., da Silva Madeira, L., & Borschiver, S. (2021). Analysis of the COVID-19 vaccine development process: an exploratory study of accelerating factors and innovative environments. Journal of Pharmaceutical Innovation, 1-17. https://doi.org/10.1007/s12247-021-09535-8

Dellepiane, N. (2007). Small Businesses for High Targets: Strategies in Industrially Exploiting the DNA–RNA Biomechanisms. In Handbook of Research on Techno-Entrepreneurship. Edward Elgar Publishing. https://doi.org/10.4337/9781847205551.00025

Dewaker, V., Morya, V. K., Kim, Y. H., Park, S. T., Kim, H. S., & Koh, Y. H. (2025). Revolutionizing oncology: the role of Artificial Intelligence (AI) as an antibody design, and optimization tools. Biomarker Research, 13(1), 52. https://doi.org/10.1186/s40364-025-00764-4

Elliott, T., Cheeseman, H. M., Evans, A. B., Day, S., McFarlane, L. R., O’Hara, J., ... & Shattock, R. J. (2022). Enhanced immune responses following heterologous vaccination with self-amplifying RNA and mRNA COVID-19 vaccines. PLoS pathogens, 18(10), e1010885. https://doi.org/10.1371/journal.ppat.1010885

Frost, I., Sati, H., Garcia-Vello, P., Hasso-Agopsowicz, M., Lienhardt, C., Gigante, V., & Beyer, P. (2023). The role of bacterial vaccines in the fight against antimicrobial resistance: an analysis of the preclinical and clinical development pipeline. The Lancet Microbe, 4(2), e113-e125. https://doi.org/10.1016/s2666-5247(22)00303-2

Gholap, A. D., Gupta, J., Kamandar, P., Bhowmik, D. D., Rojekar, S., Faiyazuddin, M., ... & Kumarasamy, V. (2023). Harnessing nanovaccines for effective immunization─ a special concern on COVID-19: facts, fidelity, and future prospective. ACS biomaterials science & engineering, 10(1), 271-297. https://doi.org/10.1021/acsbiomaterials.3c01247

Ghosh, A., Larrondo-Petrie, M. M., & Pavlovic, M. (2023). Revolutionizing vaccine development for COVID-19: a review of AI-based approaches. Information, 14(12), 665. https://doi.org/10.3390/info14120665

Gusenbauer, M., & Haddaway, N. R. (2020). Which academic search systems are suitable for systematic reviews or meta‐analyses? Evaluating retrieval qualities of Google Scholar, PubMed, and 26 other resources. Research synthesis methods, 11(2), 181-217. https://doi.org/10.1002/jrsm.1378

Haghighi, E., Abolmaali, S. S., Dehshahri, A., Mousavi Shaegh, S. A., Azarpira, N., & Tamaddon, A. M. (2024). Navigating the intricate in-vivo journey of lipid nanoparticles tailored for the targeted delivery of RNA therapeutics: a quality-by-design approach. Journal of Nanobiotechnology, 22(1), 710. https://doi.org/10.1186/s12951-024-02972-w

He, H., Chen, Z., Wang, R., Liu, X., & Liu, H. (2024). Master-Slave Heterogeneous Surveillance System Oriented to High-Speed Railway Lines Security. IEEE Sensors Journal. http://dx.doi.org/10.1109/JSEN.2024.3493932

Jafari, A., Danesh Pouya, F., Niknam, Z., Abdollahpour Alitappeh, M., Rezaei-Tavirani, M., & Rasmi, Y. (2022). Current advances and challenges in COVID-19 vaccine development: from conventional vaccines to next-generation vaccine platforms. Molecular biology reports, 49(6), 4943-4957. https://doi.org/10.1007/s11033-022-07132-7

Jain, S., Venkataraman, A., Wechsler, M. E., & Peppas, N. A. (2021). Messenger RNA-based vaccines: Past, present, and future directions in the context of the COVID-19 pandemic. Advanced drug delivery reviews, 179, 114000. https://doi.org/10.1016/j.addr.2021.114000

Kumar, R., Srivastava, V., Baindara, P., & Ahmad, A. (2022). Thermostable vaccines: An innovative concept in vaccine development. Expert Review of Vaccines, 21(6), 811-824. https://doi.org/10.1080/14760584.2022.2053678

Lefin, N., Herrera-Belén, L., Farias, J. G., & Beltrán, J. F. (2024). Review and perspective on bioinformatics tools using machine learning and deep learning for predicting antiviral peptides. Molecular diversity, 28(4), 2365-2374. https://doi.org/10.1007/s11030-023-10718-3

Legge, D. G., & Kim, S. (2021). Equitable access to COVID-19 vaccines: cooperation around research and production capacity is critical. Journal for Peace and Nuclear Disarmament, 4(sup1), 73-134. https://doi.org/10.1080/25751654.2021.1906591

Liston, A., Humblet-Baron, S., Duffy, D., & Goris, A. (2021). Human immune diversity: from evolution to modernity. Nature immunology, 22(12), 1479-1489. https://doi.org/10.1038/s41590-021-01058-1

Mao, W., Zimmerman, A., Hodges, E. U., Ortiz, E., Dods, G., Taylor, A., & Udayakumar, K. (2023). Comparing research and development, launch, and scale up timelines of 18 vaccines: lessons learnt from COVID-19 and implications for other infectious diseases. BMJ Global Health, 8(9), e012855.

Masturapratiwi, H. A., Nurhalizah, S., & Utami, H. . (2024). Assessing the Effectiveness of Vaccination Programs in Reducing Childhood Diseases. Journal of Asian-African Focus in Health, 2(3), 103–110. https://doi.org/10.71435/595705

McGoldrick, M., Gastineau, T., Wilkinson, D., Campa, C., De Clercq, N., Mallia-Milanes, A., ... & Desai, S. (2022). How to accelerate the supply of vaccines to all populations worldwide? Part I: Initial industry lessons learned and practical overarching proposals leveraging the COVID-19 situation. Vaccine, 40(9), 1215-1222. https://doi.org/10.1016/j.vaccine.2021.12.038

Nagy, A., & Alhatlani, B. (2021). An overview of current COVID-19 vaccine platforms. Computational and structural biotechnology journal, 19, 2508-2517. https://doi.org/10.1016/j.csbj.2021.04.061

Nguyen, H. X. (2025). Beyond the Needle: Innovative Microneedle-Based Transdermal Vaccination. Medicines, 12(1), 4. https://doi.org/10.3390/medicines12010004

Papania, M. J., Zehrung, D., & Jarrahian, C. (2017). Technologies to improve immunization. Plotkin's Vaccines, 1320. https://doi.org/10.1016/B978-0-323-35761-6.00068-7

Rasul, M. E., & Ahmed, S. (2023). Not all conservatives are vaccine hesitant: Examining the influence of misinformation exposure, political ideology, and flu vaccine acceptance on COVID-19 vaccine hesitancy. Vaccines, 11(3), 586. https://doi.org/10.3390/vaccines11030586

Rees, A. R. (2022). Immunological challenges of the “new” infections: Corona viruses. A New History of Vaccines for Infectious Diseases, 395. https://doi.org/10.1016/B978-0-12-812754-4.00017-0

Reynolds, L., Dewey, C., Asfour, G., & Little, M. (2023). Vaccine efficacy against SARS-CoV-2 for Pfizer BioNTech, Moderna, and AstraZeneca vaccines: a systematic review. Frontiers in Public Health, 11, 1229716. https://doi.org/10.3389/fpubh.2023.1229716

Siani, A. (2024). A Review of Global Inequities in COVID-19 Vaccination Access and Uptake. The Landscape of Global Health Inequity, 57-69. https://doi.org/10.1007/978-3-031-60502-4_6

Silva-Pilipich, N., Beloki, U., Salaberry, L., & Smerdou, C. (2024). Self-amplifying RNA: a second revolution of mRNA vaccines against COVID-19. Vaccines, 12(3), 318. https://doi.org/10.3390/vaccines12030318

Sinumvayo, J. P., Munezero, P. C., Tope, A. T., Adeyemo, R. O., Bale, M. I., Nyandwi, J. B., ... & Adedeji, A. A. (2024). Advancing vaccinology capacity: education and efforts in vaccine development and manufacturing across Africa. Vaccines, 12(7), 741. https://doi.org/10.3390/vaccines12070741

Tan, J. S., Jaffar Ali, M. N. B., Gan, B. K., & Tan, W. S. (2023). Next-generation viral nanoparticles for targeted delivery of therapeutics: Fundamentals, methods, biomedical applications, and challenges. Expert Opinion on Drug Delivery, 20(7), 955-978. https://doi.org/10.1080/17425247.2023.2228202

Tracy, L. (1995). Negotiation: an emergent process of living systems. Behavioral science, 40(1), 41-55. https://doi.org/10.1002/bs.3830400106

Wang, Y., Ling, L., Zhang, Z., & Marin-Lopez, A. (2022). Current advances in Zika vaccine development. Vaccines, 10(11), 1816. https://doi.org/10.3390/vaccines10111816

Xu, M., Wei, S., Duan, L., Ji, Y., Han, X., Sun, Q., & Weng, L. (2024). The recent advancements in protein nanoparticles for immunotherapy. Nanoscale, 16(25), 11825-11848. https://doi.org/10.1039/D4NR00537F